You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDeferasirox
Accession NumberDB01609
TypeSmall Molecule
GroupsApproved, Investigational
Description

Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose.

Structure
Thumb
Synonyms
Deferasiroxum
Exjade
ICL 670
ICL 670a
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Exjadetablet, for suspension125 mg/1oralNovartis Pharmaceuticals Corporation2005-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Exjadetablet for suspension250.0 mgoralNovartis Pharmaceuticals Canada Inc2006-11-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Exjadetablet for suspension125.0 mgoralNovartis Pharmaceuticals Canada Inc2006-11-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Exjadetablet, for suspension500 mg/1oralNovartis Pharmaceuticals Corporation2005-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Exjadetablet, for suspension250 mg/1oralNovartis Pharmaceuticals Corporation2005-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Exjadetablet for suspension500.0 mgoralNovartis Pharmaceuticals Canada Inc2006-11-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jadenutablet, film coated360 mg/1oralNovartis Pharmaceuticals Corporation2015-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Jadenutablet, film coated180 mg/1oralNovartis Pharmaceuticals Corporation2015-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Jadenutablet, film coated90 mg/1oralNovartis Pharmaceuticals Corporation2015-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number201530-41-8
WeightAverage: 373.3615
Monoisotopic: 373.106255983
Chemical FormulaC21H15N3O4
InChI KeyInChIKey=BOFQWVMAQOTZIW-UHFFFAOYSA-N
InChI
InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
IUPAC Name
4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
SMILES
OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenyl-1,3,4-triazoles. These are organic compounds containing a 1,3,4-triazole substituted by a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTriazoles
Direct ParentPhenyl-1,3,4-triazoles
Alternative Parents
Substituents
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
PharmacodynamicsDeferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.
Mechanism of actionTwo molecules of deferasirox are capable of binding to 1 atom of iron. Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys.
AbsorptionThe absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
Volume of distribution
  • 14.37 ± 2.69 L
Protein bindingDeferasirox is highly (~99%) protein bound almost exclusively to serum albumin.
Metabolism

Hepatic. CYP450-catalyzed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion.

Route of eliminationDeferasirox and metabolites are primarily (84% of the dose) excreted in the feces. Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose).
Half lifeThe mean elimination half-life ranged from 8 to 16 hours following oral administration.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.993
Blood Brain Barrier+0.8508
Caco-2 permeable+0.5089
P-glycoprotein substrateNon-substrate0.7808
P-glycoprotein inhibitor INon-inhibitor0.894
P-glycoprotein inhibitor IINon-inhibitor0.8431
Renal organic cation transporterNon-inhibitor0.8708
CYP450 2C9 substrateNon-substrate0.7212
CYP450 2D6 substrateNon-substrate0.8686
CYP450 3A4 substrateNon-substrate0.6466
CYP450 1A2 substrateNon-inhibitor0.5802
CYP450 2C9 inhibitorNon-inhibitor0.7105
CYP450 2D6 inhibitorNon-inhibitor0.8221
CYP450 2C19 inhibitorNon-inhibitor0.5918
CYP450 3A4 inhibitorNon-inhibitor0.8179
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5717
Ames testNon AMES toxic0.6607
CarcinogenicityNon-carcinogens0.8519
BiodegradationNot ready biodegradable0.9524
Rat acute toxicity2.1119 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9684
hERG inhibition (predictor II)Non-inhibitor0.9072
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet for suspensionoral125.0 mg
Tablet for suspensionoral250.0 mg
Tablet for suspensionoral500.0 mg
Tablet, for suspensionoral125 mg/1
Tablet, for suspensionoral250 mg/1
Tablet, for suspensionoral500 mg/1
Tablet, film coatedoral180 mg/1
Tablet, film coatedoral360 mg/1
Tablet, film coatedoral90 mg/1
Prices
Unit descriptionCostUnit
Exjade 500 mg tablet78.61USD tablet
Exjade 250 mg tablet39.3USD tablet
Exjade 125 mg tablet19.65USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada22559512006-10-102017-06-24
United States64655041999-04-052019-04-05
United States65967501997-06-242017-06-24
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point116-117 °CNot Available
water solubility0.038 mg/mL at 37 °CYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.52HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0343 mg/mLALOGPS
logP4.01ALOGPS
logP4.74ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.55ChemAxon
pKa (Strongest Basic)0.19ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area108.47 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity125.32 m3·mol-1ChemAxon
Polarizability38.52 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Rajendra Suryabhan Patil, Kishore Charugundla, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson, “SUBSTANTIALLY PURE DEFERASIROX AND PROCESSES FOR THE PREPARATION THEREOF.” U.S. Patent US20110171138, issued July 14, 2011.

US20110171138
General ReferencesNot Available
External Links
ATC CodesV03AC03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Deferasirox.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Deferasirox.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Deferasirox.
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Deferasirox.
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Deferasirox.
AlendronateThe risk or severity of adverse effects can be increased when Alendronate is combined with Deferasirox.
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Deferasirox.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Deferasirox.
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Deferasirox.
Aluminum hydroxideThe therapeutic efficacy of Deferasirox can be decreased when used in combination with Aluminum hydroxide.
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Deferasirox.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Deferasirox.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Deferasirox.
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Deferasirox.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Deferasirox.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Deferasirox.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Deferasirox.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Deferasirox.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Deferasirox.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Deferasirox.
ArmodafinilThe serum concentration of Armodafinil can be decreased when it is combined with Deferasirox.
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Deferasirox.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Deferasirox.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Deferasirox.
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Deferasirox.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Deferasirox.
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Deferasirox.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Deferasirox.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Deferasirox.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Deferasirox.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Deferasirox.
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Deferasirox.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Deferasirox.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Deferasirox.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Deferasirox.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Deferasirox.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Deferasirox.
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Deferasirox.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Deferasirox.
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Deferasirox.
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Deferasirox.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Deferasirox.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Deferasirox.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Deferasirox.
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Deferasirox.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Deferasirox.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Deferasirox.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Deferasirox.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Deferasirox.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Deferasirox.
CholestyramineThe serum concentration of Deferasirox can be decreased when it is combined with Cholestyramine.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Deferasirox.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Deferasirox.
Citric AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Deferasirox.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Deferasirox.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Deferasirox.
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Deferasirox.
ClodronateThe risk or severity of adverse effects can be increased when Clodronate is combined with Deferasirox.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Deferasirox.
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Deferasirox.
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Deferasirox.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Deferasirox.
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Deferasirox.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Deferasirox.
ColesevelamThe serum concentration of Deferasirox can be decreased when it is combined with Colesevelam.
ColestipolThe serum concentration of Deferasirox can be decreased when it is combined with Colestipol.
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Deferasirox.
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Deferasirox.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Deferasirox.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Deferasirox.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Deferasirox.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox.
Cyproterone acetateThe serum concentration of Cyproterone acetate can be decreased when it is combined with Deferasirox.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deferasirox.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Deferasirox.
DacarbazineThe serum concentration of Dacarbazine can be increased when it is combined with Deferasirox.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Deferasirox.
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Deferasirox.
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Deferasirox.
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Deferasirox.
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Deferasirox.
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Deferasirox.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Deferasirox.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Deferasirox.
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Deferasirox.
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Deferasirox.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Deferasirox.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Deferasirox.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Deferasirox.
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Deferasirox.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Deferasirox.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Deferasirox.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Deferasirox.
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Deferasirox.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Deferasirox.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Deferasirox.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Deferasirox.
DoxazosinThe serum concentration of Doxazosin can be decreased when it is combined with Deferasirox.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Deferasirox.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Deferasirox.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Deferasirox.
Edetic AcidThe risk or severity of adverse effects can be increased when Edetic Acid is combined with Deferasirox.
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox.
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Deferasirox.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Deferasirox.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Deferasirox.
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Deferasirox.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Deferasirox.
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Deferasirox.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Deferasirox.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Deferasirox.
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Deferasirox.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Deferasirox.
EstropipateThe serum concentration of Estropipate can be decreased when it is combined with Deferasirox.
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Deferasirox.
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Deferasirox.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Deferasirox.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Deferasirox.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Deferasirox.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Deferasirox.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Deferasirox.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Deferasirox.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Deferasirox.
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Deferasirox.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Deferasirox.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Deferasirox.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Deferasirox.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Deferasirox.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Deferasirox.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Deferasirox.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Deferasirox.
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Deferasirox.
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Deferasirox.
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Deferasirox.
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Deferasirox.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Deferasirox.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Deferasirox.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Deferasirox.
FluvoxamineThe serum concentration of Fluvoxamine can be increased when it is combined with Deferasirox.
Fondaparinux sodiumThe risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Deferasirox.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Deferasirox.
FosaprepitantThe serum concentration of Fosaprepitant can be decreased when it is combined with Deferasirox.
FosphenytoinThe serum concentration of Deferasirox can be decreased when it is combined with Fosphenytoin.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Deferasirox.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Deferasirox.
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Deferasirox.
Halobetasol PropionateThe risk or severity of adverse effects can be increased when Halobetasol Propionate is combined with Deferasirox.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Deferasirox.
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Deferasirox.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Deferasirox.
HydrocortamateThe risk or severity of adverse effects can be increased when Hydrocortamate is combined with Deferasirox.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Deferasirox.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Deferasirox.
IbandronateThe risk or severity of adverse effects can be increased when Ibandronate is combined with Deferasirox.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Deferasirox.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Deferasirox.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Deferasirox.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Deferasirox.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Deferasirox.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Deferasirox.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Deferasirox.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Deferasirox.
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Deferasirox.
IsosorbideThe serum concentration of Isosorbide can be decreased when it is combined with Deferasirox.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Deferasirox.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Deferasirox.
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Deferasirox.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Deferasirox.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Deferasirox.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Deferasirox.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Deferasirox.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Deferasirox.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Deferasirox.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Deferasirox.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Deferasirox.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Deferasirox.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Deferasirox.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Deferasirox.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Deferasirox.
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Deferasirox.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Deferasirox.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Deferasirox.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Deferasirox.
MACITENTANThe serum concentration of MACITENTAN can be decreased when it is combined with Deferasirox.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Deferasirox.
Medroxyprogesterone AcetateThe serum concentration of Medroxyprogesterone Acetate can be decreased when it is combined with Deferasirox.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Deferasirox.
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Deferasirox.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Deferasirox.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Deferasirox.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Deferasirox.
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Deferasirox.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Deferasirox.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Deferasirox.
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Deferasirox.
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Deferasirox.
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Deferasirox.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Deferasirox.
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Deferasirox.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Deferasirox.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Deferasirox.
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Deferasirox.
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Deferasirox.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Deferasirox.
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Deferasirox.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Deferasirox.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Deferasirox.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Deferasirox.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Deferasirox.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Deferasirox.
NorethindroneThe serum concentration of Norethindrone can be decreased when it is combined with Deferasirox.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Deferasirox.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Deferasirox.
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Deferasirox.
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Deferasirox.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deferasirox.
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Deferasirox.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Deferasirox.
PamidronateThe risk or severity of adverse effects can be increased when Pamidronate is combined with Deferasirox.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Deferasirox.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Deferasirox.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Deferasirox.
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Deferasirox.
PhenobarbitalThe serum concentration of Deferasirox can be decreased when it is combined with Phenobarbital.
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Deferasirox.
PhenytoinThe serum concentration of Deferasirox can be decreased when it is combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Deferasirox.
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Deferasirox.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Deferasirox.
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Deferasirox.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Deferasirox.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Deferasirox.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Deferasirox.
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Deferasirox.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Deferasirox.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Deferasirox.
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Deferasirox.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Deferasirox.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Deferasirox.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Deferasirox.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Deferasirox.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Deferasirox.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Deferasirox.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Deferasirox.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Deferasirox.
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Deferasirox.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Deferasirox.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Deferasirox.
Repository corticotropinThe risk or severity of adverse effects can be increased when Repository corticotropin is combined with Deferasirox.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Deferasirox.
RifampicinThe serum concentration of Deferasirox can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Deferasirox.
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Deferasirox.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Deferasirox.
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Deferasirox.
RitonavirThe serum concentration of Deferasirox can be decreased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Deferasirox.
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Deferasirox.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Deferasirox.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Deferasirox.
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Deferasirox.
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Deferasirox.
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Deferasirox.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Deferasirox.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Deferasirox.
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Deferasirox.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Deferasirox.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Deferasirox.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Deferasirox.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Deferasirox.
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Deferasirox.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Deferasirox.
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Deferasirox.
StiripentolThe serum concentration of Stiripentol can be decreased when it is combined with Deferasirox.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Deferasirox.
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Deferasirox.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Deferasirox.
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Deferasirox.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Deferasirox.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Deferasirox.
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Deferasirox.
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Deferasirox.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Deferasirox.
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Deferasirox.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Deferasirox.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Deferasirox.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Deferasirox.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Deferasirox.
ThiothixeneThe serum concentration of Thiothixene can be increased when it is combined with Deferasirox.
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Deferasirox.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Deferasirox.
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Deferasirox.
TiludronateThe risk or severity of adverse effects can be increased when Tiludronate is combined with Deferasirox.
TinzaparinThe risk or severity of adverse effects can be increased when Tinzaparin is combined with Deferasirox.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Deferasirox.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Deferasirox.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Deferasirox.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Deferasirox.
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Deferasirox.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Deferasirox.
TorasemideThe serum concentration of Torasemide can be increased when it is combined with Deferasirox.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Deferasirox.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Deferasirox.
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Deferasirox.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Deferasirox.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Deferasirox.
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Deferasirox.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Deferasirox.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Deferasirox.
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Deferasirox.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Deferasirox.
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Deferasirox.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Deferasirox.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Deferasirox.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Deferasirox.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Deferasirox.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Deferasirox.
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Deferasirox.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Deferasirox.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Deferasirox.
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Deferasirox.
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Deferasirox.
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Deferasirox.
ZoledronateThe risk or severity of adverse effects can be increased when Zoledronate is combined with Deferasirox.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Deferasirox.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Deferasirox.
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Deferasirox.
Food Interactions
  • Dispersion in carbonated drinks or milk is not recommended due to foaming and slow dispersion, respectively.
  • Food causes inconsistent increases in the bioavailability of this product.
  • Tablets should be completely dispersed in water, orange juice or apple juice and the resulting suspension should be ingested immediately (after swallowing the suspension, any residue should be resuspended in a small volume of liquid and swallowed).
  • Tablets should be taken on an empty stomach at least 30 minutes before a meal, preferably at the same time everyday.

Targets

1. Iron

Kind: Small molecule

Organism: Human

Pharmacological action: yes

Actions: chelator

Components

Name UniProt ID Details

References:

  1. Wang T, Gao C, Chen BA: [Deferasirox—a new oral iron chelator—review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Oct;18(5):1359-64. Pubmed
  2. Ibrahim AS, Spellberg B, Edwards J Jr: Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008 Dec;21(6):620-5. Pubmed
  3. Devanur LD, Evans RW, Evans PJ, Hider RC: Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy. Biochem J. 2008 Jan 15;409(2):439-47. Pubmed
  4. Lebitasy M, Ampe E, Hecq JD, Karmani L, Nick H, Galanti L: Ability of deferasirox to bind iron during measurement of iron. Clin Chem Lab Med. 2010 Mar;48(3):427-9. Pubmed
  5. Yang LP, Keam SJ, Keating GM: Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30. Pubmed
  6. Choudhry VP, Naithani R: Current status of iron overload and chelation with deferasirox. Indian J Pediatr. 2007 Aug;74(8):759-64. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Skerjanec A, Wang J, Maren K, Rojkjaer L: Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol. 2010 Feb;50(2):205-13. Epub 2009 Nov 25. Pubmed

Comments
comments powered by Disqus
Drug created on August 29, 2007 13:21 / Updated on September 16, 2013 17:15